SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Google

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Treatment hope for cognitive symptoms in Parkinson's disease
Tues May 17th - Ultra-powerful 7T MRI scanners could help to identify those patients with conditions such as Parkinson's disease who would benefit from new treatments for cognitive symptoms that were previously untreatable, British researchers report today. More
E-cigarettes as effective as patches for pregnant women
Tues May 17th - E-cigarettes can help pregnant women to stop smoking and are as safe as nicotine patches, according to new UK research. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Trials target care for critically ill Covid-19 patients

Thursday April 16th, 2020

Two UK universities have embarked on a major clinical trial to study alternatives to ventilator care for patients critically ill with Covid-19.

Warwick University and Queen's University, Belfast, aim to involve 4,000 patients in the study.

The researchers want to examine the prospects for non-invasive treatments such as high-flow nasal oxygen or masks driven by oxygen.

Patients will be offered the chance to participate at an early stage in their hospital care – and would then be assigned a treatment at random.

Chief investigator Professor Gavin Perkins, from Warwick, said: “Clinical trials are the only way to safely study these interventions and to offer patients the additional protections necessary within the carefully controlled environment of a clinical trial, and are the best way to quickly find effective supportive interventions for this global pandemic.”

* The first patient has been treated with a new monoclonal antibody treatment aimed at tackling acute respiratory distress syndrome, US doctors have reported.

Gimsilumab was released last month and targets granulocyte-colony stimulating factor, which is thought to drive hyper-inflammation of the lungs.

The drug has previously undergone phase 1 studies to test for safety and tolerability.

It is now subject to a randomised control trial, aimed at involving 270 patients.

Researcher Professor Gerard Criner, of Temple University, Philadelphia, USA, said: "Emerging evidence suggests that GM-CSF may contribute to clinical worsening in COVID-19. We are proud to participate in this clinical trial testing gimsilumab in this vulnerable patient population."

https://warwick.ac.uk/fac/sci/med/research/ctu/trials/recovery-rs/

Tags: A&E | Flu & Viruses | North America | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES